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Abstract
Background: Chronic upper respiratory tract infections (cURTI) are very frequent illnesses which occur at any age of
life. In elderly, cURTI are complicated by immunosenescence, with involvement of lung immune responsiveness.
Results: In the present study, 51 elderly (age range: 66–86) and 51 young (age range 24–58) cURTI patients underwent
a single cycle (two weeks) of inhalatory therapy with salt-bromide-iodine thermal water in the thermal station
“Margherita di Savoia” (Margherita di Savoia, BAT, Italy). Peripheral blood serum cytokines and clinical assessment
were performed before therapy (T0) and after six months (T1) and 12 months (T2) from inhalatory treatment. In
both elderly and young patients, at baseline an increased release of T helper (h)1-related cytokines [interleukin
(IL)-2 and interferon-γ] and of Th2-related cytokine (IL-4) was documented. Inhalatory treatment reduced the
excessive secretion of all the above-cited cytokines. IL-10 values were above normality at all times considered in
both groups of patients. In addition, an increase in IL-17 and IL-21 serum levels following therapy was observed
in both groups of patients. Pro-inflammatory cytokine (IL-1β, IL-6, IL-8 and tumor necrosis factor-α) baseline
values were lower than normal values at T0 in both elderly and young cURTI patients. Their levels increased
following inhalatory treatment.
Clinically, at T2 a dramatic reduction of frequency of upper respiratory tract infections was recorded in both
groups of patients.
Conclusion: Thermal water inhalation is able to modulate systemic immune response in elderly and young cURTI
patients, thus reducing excessive production of Th1 and Th2-related cytokines, on the one hand. On the other
hand, increased levels of IL-21 (an inducer of Th17 cells) and of IL-17 may be interpreted as a protective mechanism,
which likely leads to neutrophil recruitment in cURTI patients. Also restoration of pro-inflammatory cytokine release
following inhalatory therapy may result in microbe eradication. Quite importantly, the maintenance of high levels
of IL-10 during the follow-up would suggest a consistent regulatory role of this cytokine in attenuating the
pro-inflammatory arm of the immune response.
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Background
Chronic upper respiratory tract infections (cURTI) are
recurrent illnesses which involve nose, sinuses, pharynx,
and larynx. Tonsillitis, pharyngitis, rhinitis, sinusitis, otitis,
common cold and, sometimes, bronchial complications
are the major clinical signs with periodical exacerbations
in winter period [1]. Among viruses, the most common is
Rhinovirus but also Adenovirus, Parainfluenza virus, En-
terovirus and Respiratory Syncitial virus can be isolated
from cURTI patients [2, 3]. Among bacteria, group A
Streptococcus (S.), S. pneumonia, S. pyogens, Haemophilus
influenza have frequently been detected in cURTI patients
[2, 3]. Evidence has been provided that cURTI are very
frequent diseases, involving millions of people annually
and all ages are affected [4]. In elderly, cURTI are compli-
cated by the decline of immune response in this period of
life [5, 6]. In fact, multiple disorders of the innate and
adaptive immunity have been described in ageing, thus in-
creasing frequency of infections [7, 8].
Immunosenescence has recently been termed as senes-
cent immune remodeling (SIR) [9, 10], and, in a recent
review, Denkinger et al. [11–14] have pointed out the
major immune alterations of T and B cells in elderly.
With regard to modifications of innate immunity in elderly,
a condition of low grade inflammation has been reported
and termed as ‘inflammaging’ [15]. It has been demon-
strated that ‘inflammageing’ also leads to hematopoietic
stem cell (HSC) exhaustion and bone marrow failure [16],
as also shown in mice following total body irradiation [17].
Conclusively, both low grade inflammation and HSC aging
may be involved in SIR development [11].
With special reference to aged lungs, release of pro-
inflammatory cytokines in the absence of a given stimu-
lus may contribute to tissue destruction and loss of
elasticity [18]. Viceversa, in the presence of injurious
stimuli (e.g., viruses and bacteria) elevated basal produc-
tion of cytokines hampers release of pro-inflammatory
mediators, as observed in aged and knockout animals
[19–26]. Just recently, old dendritic cells (DCs) have been
shown to contribute to chronic airway inflammation, re-
leasing pro-inflammatory mediators, mostly tumor necro-
sis factor (TNF)-α, which affects primarily bronchial
epithelial cell function in vitro, enhancing the epithelial
barrier permeability, thus increasing susceptibility to in-
fectious respiratory disease in ageing [27]. Finally, naïve
CD4+ and CD8+ cells are reduced in aged animals and
humans with an impaired conversion towards memory
cells able to respond to new antigens in the context of
respiratory tract [28, 29].
A series of papers have investigated the local immune
response in cURTI, especially, with regard to chronic
rhinosinusitis (CRS). Group 2 innate lymphoid cells
(ILCs2) have been isolated in the nasal mucosa of CRS pa-
tients which correlated with T helper (h)-2 cell number,
serum total IgE and allergic disease, such as asthma [30].
Furthermore, ILCs2 may account for polyp formation in
these patients. In CRS with polyps, elevated levels of tissue
interleukin (IL)-21 have been detected as products of Th1
and Th17 cells [31]. IL-21 correlated with disease severity,
B cell production (IgG and IgA) and protracted inflamma-
tion of the mucosa. In patients with eosinophilic CRS, in-
creased tissue levels of IL-25 have been detected [32]. Th2
and Th9 cells, which express IL-17RB mRNA levels and
IL-25, seem to contribute to eosinophilia. Another study
has reported production of IL-25, IL-33 and thymic stromal
lymphoietin by sinus epithelial cells in response to microbial
stimulation or airway injury in patients with CRS [33]. The
above cited cytokine network seems to favor regional Th2-
mediated inflammation. According to other researchers, the
heavy infiltration of DCs in CRS with polyps may account
for the Th2-mediated inflammation in this disease [34].
Finally, a defect of natural killer (NK) cells was detected
in CRS patients refractory to treatment [35]. The inability
of NK cells to degranulate and release interferon (IFN)-γ
and TNF-α may account for the reduced cytotoxicity
against target cells, even including infected cells.
Thermal water inhalation to patients with cURTI is a
conventional treatment with long tradition [36]. The
anti-inflammatory effects of thermal water are supported
by current literature. Treatment with sulphurous ther-
mal water in patients with rhinitis led to a reduction of
polymorphonuclear cells in nasal mucosa [37]. Bromide-
iodine thermal water decreased serum IgE and increased
serum IgA in patients with allergic rhinitis [38]. Also in
patients with chronic obstructive pulmonary disease
(COPD) (a lower respiratory tract disease), inhalation of
salt-bromide-iodine thermal water dramatically reduced
neutrophil content in sputum [39]. These findings have
suggested an anti-inflammatory effect exerted by thermal
water inhalation in chronic respiratory disease but mecha-
nisms of action have not yet been elucidated.
Aim of this study is to evaluate serum cytokines and clin-
ical response of elderly and young cURTI patients to inhal-
ation therapy with salt-bromide-iodine thermal water. Of
note, cytokines for their pleiotropic effects seem to represent
an appropriate biomarker of systemic inflammation in
cURTI. Results will show that normalization of Th1 and
Th2 exaggerated cytokine responses, increase in IL-21 pro-
duction and recovery of impaired pro-inflammatory cyto-
kine secretion likely lead to a dramatic clinical improvement
in terms of partial or total abrogation of infectious recur-
rences. A hypothetical model of the mechanisms of action
of thermal water inhalation is also illustrated.
Results
Fifty-one elderly patients (mean age 68 years) and 51
young patients (mean age 48 years) were enrolled for
this study.
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Th1-related cytokines
Elderly patients
Serum levels of IL-12 significantly increased in elderly
patients at T2 (p < 0.01), being values undetectable at
T1 and above normality at T0 [values of young donors
(controls): 0 pg/ml; values of elderly (controls): 0.8–
3.8 pg/ml)] [Fig. 1a].
Serum levels of IL-2 were undetectable at T1 and signifi-
cantly decreased at T2 (p < 0.05) in comparison to more
elevated T0 values [values of young donors (controls):
0 pg/ml; values of elderly (controls): 4–20 pg/ml] [Fig. 1b].
A different profile was observed in the case of IFN-γ
evaluation since its serum concentration dramatically
dropped at T2 (p < 0.0001) when compared to higher
amounts at T0 and T1 [values of young donors (controls):
0 pg/ml; values of elderly (controls): 0–7 pg/ml] [Fig. 1c].
Young patients
The response pattern of IL-12 was quite similar to that
detected in the case of elderly patients with increasing
cytokine values at T2 (p < 0.01) [Fig. 2a].
With regard to IL-2 serum levels, amounts of this
cytokine significantly decreased at T1 and T2 (p < 0.01),
being values almost undetectable [Fig. 2b].
IFN-γ serum level profile overlapped that noted in the
case of elderly patients [Fig. 2c].
Conclusively, at T0 in both elderly and young cURTI
patients Th1-related cytokines (IL-2 and IFN-γ) were




Elevated levels of IL-4, above normal values at T0 and
T1, significantly decreased at T2 (p < 0.0001) [values of
young donors (controls); 0.3–0.9 pg/ml; value of elderly
(controls): 0–0.1 pg/ml] (Fig. 3).
Young patients
The above reported effects were more evident in young
patients since IL-4 values, higher than the respective
counterpart at T0, significantly dropped at T1 and T2
(almost undetectable) (p < 0.05) (Fig. 4).
In conclusion, reduction of IL-4, following inhalatory
treatment, was more pronounced in young patients
where baseline values were even higher than the elderly
counterpart at T0.
Fig. 1 Determination of Th1-related cytokines in sera of cURTI elderly patients. Panel a: IL-12 serum level measurement; panel b: IL-2 serum level
measurement; panel c: IFN-γ serum level measurement. Serum cytokines were assayed by flex set kit using a citofluorimetry (FACS Aria III) as described
in material and methods. T0 = before treatment, T1 = after six months, T2 = after one year of treatment. Symbols indicate statistical analysis between
samples performed by Student’s t-test (GraphPad Prism 5.0 software) and values with p < 0.05 were considered significantly
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Fig. 2 Determination of Th1-related cytokines in sera of cURTI young patients. Panel a: IL-12 serum level measurement; panel b: IL-2 serum level
measurement; panel c: IFN-γ serum level measurement. Serum cytokines were assayed by flex set kit using a citofluorimetry (FACS Aria III) as described
in material and methods. T0 = before treatment, T1 = after six months, T2 = after one year of treatment. Symbols indicate statistical analysis between
samples performed by Student’s t-test (GraphPad Prism 5.0 software) and values with p < 0.05 were considered significantly
Fig. 3 Determination of Th2-related cytokine in sera of cURTI elderly
patients. IL-4 serum level measurement. Serum cytokines were assayed
by flex set kit using a citofluorimetry (FACS Aria III) as described in
material and methods. T0 = before treatment, T1 = after six months,
T2 = after one year of treatment. Symbols indicate statistical analysis
between samples performed by Student’s t-test (GraphPad Prism 5.0
software) and values with p < 0.05 were considered significantly
Fig. 4 Determination of Th2-related cytokine in sera of cURTI young
patients. IL-4 serum level measurement. Serum cytokines were assayed
by flex set kit using a citofluorimetry (FACS Aria III) as described in
material and methods. T0 = before treatment, T1 = after six months,
T2 = after one year of treatment. Symbols indicate statistical analysis
between samples performed by Student’s t-test (GraphPad Prism 5.0
software) and values with p < 0.05 were considered significantly
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Evaluation of the IL-10/IL-17/IL-21 axis
Elderly patients
IL-10 values were above normality at all times considered
even if a trend to decrease was observed at T1 and T2
[values of young donors (controls): 6–22 pg/ml; values of
elderly (controls): 4–20 pg/ml] [Fig. 5a].
Conversely, values of IL-17 increased at T2 (p < 0.05)
even above normal ranges [values of young donors
(controls): 0 pg/ml; values of elderly (controls): 0 pg/ml]
[Fig. 5b].
The previous finding was corroborated by a dramatic ele-
vation of IL-21 (p < 0.01), a Th17 inducer (see discussion)
at T2, while values at T0 and T1 were almost undetectable
[values of young donors (controls): 6–18 pg/ml; values of
elderly (controls): 0 pg/ml] [Fig. 5c].
Young patients
IL-10 profile was quite similar to that of elderly patients,
being values above normality at all times considered
[Fig. 6a].
IL-17 exhibited lower values at T0 which increased at
T1 (p < 0.05) and T2 (p < 0.01) in a very significant man-
ner. No differences were detected between T1 and T2
serum concentrations [Fig. 6b].
IL-21 amounts were higher at T0 than normal controls
and elderly counterpart. Values were undetectable at T1
but significantly increased at T2 (p < 0.05) [Fig. 6c].
Taken together, these findings suggest that IL-10 re-
sponse was very much elevated at all times in both
groups of patients. In elderly, IL-21 increase at T2 seems
to correlate with IL-17 elevation. However, the former
cytokine was completely absent at T0 and T1. In young
patients, IL-21 levels dropped at T1, but rose at T2.
Evaluation of pro-inflammatory cytokines
Elderly patients
IL-1β values significantly increased at T2 (p < 0.01) in
comparison to very low amounts at T0 and T1 [values
of young donors (controls): 3–45 pg/ml; values of elderly
(controls): 0,4–2,8 pg/ml] [Fig. 7a].
With regard to TNF-α, undetectable levels of this
cytokine at T0 and T1 dramatically increased at T2 (p <
0.0001) [values of young donors (controls): 0,2–4,5 pg/ml;
values of elderly (controls): 1–3,2 pg/ml] [Fig. 7b].
IL-6 was undetectable at T0 with a rise of values at T1
and T2 (p < 0.0001) [values of young donors (controls):
27–69 pg/ml; values of elderly (controls): 4–9 pg/ml]
[Fig. 7c].
Fig. 5 Determination of IL-10, IL-17 and IL-21 in sera of cURTI elderly patients. Panel a: IL-10 serum level measurement; panel b: IL-17 serum level
measurement; panel c: IL-21 serum level measurement. Serum cytokines were assayed by flex set kit using a citofluorimetry (FACS Aria III) as
described in material and methods. T0 = before treatment, T1 = after six months, T2 = after one year of treatment. Symbols indicate statistical
analysis between samples performed by Student’s t-test (GraphPad Prism 5.0 software) and values with p < 0.05 were considered significantly
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In the case of IL-8, values significantly increased at
T1 and T2 (p < 0.01) when compared to undetectable
levels at T0 [values of young donors (controls): 1382–
7550 pg/ml; values of elderly (controls): 16–30 pg/ml]
[Fig. 7d].
Young patients
IL-1β baseline values were below normal ranges and an
increase was noted at T2 (p < 0.05) [Fig. 8a].
TNF-α values were undetectable at T0 and at T1 but
dramatically increased at T2 (p < 0.05) [Fig. 8b].
IL-6 progressively increased from T0 up to T2 (p <
0.0001) but values were below normal ranges [Fig. 8c].
IL-8 progressively increased at T1 and T2 in comparison
to baseline values (p < 0.05 and p < 0.0001, respectively),
with T2 values falling within normal ranges [Fig. 8d].
The overall findings suggest that in elderly and young
cURTI patients the inflammatory cytokine pathway was
impaired at T0 but restored by inhalatory treatment at
T1 and T2 except for IL-6.
Clinical evaluation
Among 48 elderly cURTI patients, 33 attained a full
recovery of clinical manifestations at T2 (no infectious
episodes) in comparison to 3 events at T0. In 15 of
them, only one episode was recorded at T2 when com-
pared to 2.2 infectious events at T0.
In the young patient counterpart, 29 individuals exhib-
ited a full recovery (no episodes at T2 vs 4 events at T0).
In the remaining 19 cases, 1.6 episodes at T2 vs 4 events
at T0 were recorded.
Results are summarized in Table 1.
Discussion
cURTI are very common pathologies which afflict both
young and old individuals. In elderly, the decline of im-
mune response may aggravate the clinical course of
cURTI because of the prolonged persistence of viruses
and bacteria in the lung [40]. For the above reasons, in
the present study we have compared the immune and
clinical responses of elderly cURTI patients to those of a
younger counterpart following inhalatory therapy with
bromide-iodine thermal water.
Serum cytokine assessment immediately before and after
six months and one year after a single cycle of inhalatory
therapy has allowed monitoring both innate and adaptive
arms of the immune response in both groups of patients.
It is well known that in response to a microbial stimu-
lus, DCs acting as antigen presenting cells release IL-12
for the polarization of Th1 cells [41–43]. On these bases,
Fig. 6 Determination of IL-10, IL-17 and IL-21 in sera of cURTI young patients. Panel a: IL-10 serum level measurement; panel b: IL-17 serum level
measurement; panel c: IL-21 serum level measurement. Serum cytokines were assayed by flex set kit using a citofluorimetry (FACS Aria III) as described
in material and methods. T0 = before treatment, T1 = after six months, T2 = after one year of treatment. Symbols indicate statistical analysis between
samples performed by Student’s t-test (GraphPad Prism 5.0 software) and values with p < 0.05 were considered significantly
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we have evaluated IL-12 in sera from both groups of
cURTI patients. IL-12 values are above normal ranges in
both elderly and young patients with a significant rise at
T2. In elderly, Th1-related cytokines are released in ex-
cess as in the case of IL-2 even if, a trend to its decrease
can be observed at T2. In the case of IFN-γ, elevated
values at T0 and T1 significantly decrease at T2. This
pattern of response is similar to that seen in young pa-
tients, thus suggesting that in cURTI no differences are
present between older and young patients in relation
to Th1 function.
Quite interestingly, IL-4 evaluation in elderly and
young patients, as a product of Th2 cells [44, 45], indi-
cates that its release is above normality at T0 and at T1
but decreases at T2.
All together, our data suggest that both cellular and
humoral adaptive immunity is involved in cURTI and
no major differences can be seen between older and
young patients in terms of functional changes following
therapy.
To better clarify the immunological effects exerted by
the inhalatory treatment, the role of IL-10 needs to be
elucidated. IL-10, an anti-inflammatory cytokine, is pre-
dominantly produced by regulatory T cells as well as by
Th2 cells [46, 47]. Both in elderly and young cURTI pa-
tients, values of IL-10 are higher than controls and, it is
likely to hypothesize that inhalatory treatment contributes
to maintain its continuous production. In fact, reduction
of major cytokines such as IL-2, IL-4 and IFN-γ may
result from the IL-10-mediated down-regulation during
treatment. This effect may also lead to a reduction of
lung and systemic immunopathology, attenuating the
prolonged inflammatory effects of IFN-γ [48] as well as
the IL-4-mediated allergic-inflammatory respiratory re-
sponses [49]. Mostly, in young cURTI patients, reduced
levels of IL-2 thanks to inhalatory treatment may contrib-
ute to a diminished expansion of Th1 and Th2 antigen-
specific cells [45].
In this framework, we have evaluated IL-21 release
since it seems to act as an inducer of Th17 cells which,
in turn, are able to produce another wave of IL-21 [50, 51].
The increased levels of IL-21 and IL-17 at T2 in both
groups of patients may be interpreted as a protective
mechanism rather than detrimental. In fact, evidence has
Fig. 7 Determination of pro-inflammatory cytokines in sera of cURTI elderly patients. Panel a: IL-1β serum level measurement; panel b: TNF-α serum
level measurement; panel c: IL-6 serum level measurement; panel d: IL-8 serum level measurement. Serum cytokines were assayed by flex set kit using
a citofluorimetry (FACS Aria III) as described in material and methods. T0 = before treatment, T1 = after six months, T2 = after one year of treatment.
Symbols indicate statistical analysis between samples performed by Student’s t-test (GraphPad Prism 5.0 software) and values with p < 0.05 were
considered significantly
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been reported that in animal models IL-17 plays a critical
role in host defence against bacteria in the airways [52].
Protection seems to depend on Th17-mediated release of
neutrophil-mobilizing cytokines and attraction of neutro-
phils to antigenic sites, where they neutralize microorgan-
isms. In this connection, evidence has been provided that
reduced release of IL-17 may increase susceptibility to bac-
terial infections in smokers with COPD [52].
Evaluation of pro-inflammatory cytokines in cURTI
patients has led to results of pathogenic as well as clinical
relevance. In fact, especially in elderly patients all serum
cytokine amounts (IL-1β, IL-8, TNF-α and IL-6) are re-
duced but they increase following inhalation therapy,
even including IL-6, which, however, still remains below
normality. In the younger patient counterpart, values of
IL-1β, IL-6, IL-8 and TNF-α are below normality, with an
increase of levels at the end of therapy. Inflammatory
responses mediated by cytokines are of paramount im-
portance for microbe eradication [53] and, in both cURTI
patients restoration of the pro-inflammatory pathway by
inhalation therapy may contribute to clinical improvement
(see below). Several cell types in the lung or systemic-
ally can produce the above mediators, even including,
monocytes/macrophages, DCs, neutrophils and epithe-
lial cells. It is hard to identify in this work the actual
cellular source of pro-inflammatory cytokines, but we
are tempted to hypothesize that neutrophils activated
by IL-17 can act as important players in the restoration
of the pro-inflammatory pathway in cURTI. On the
other hand, IL-10 elevated levels may contribute to the
containment of excessive pro-inflammatory functions
by neutrophils, assuming that these cells are the actual
producers of pro-inflammatory cytokines.
Clinically, inhalatory treatment seems to be very effect-
ive in cURTI patients, as indicated by absence or reduc-
tion of infectious episodes at T2. Of note, in the young
patients response to treatment seems to be more effective.
The clinical improvement is long-lasting continuing after
Fig. 8 Determination of pro-inflammatory cytokines in sera of cURTI young patients. Panel a: IL-1β serum level measurement; panel b: TNF-α
serum level measurement; panel c: IL-6 serum level measurement; panel d: IL-8 serum level measurement. Serum cytokines were assayed by flex
set kit using a citofluorimetry (FACS Aria III) as described in material and methods. T0 = before treatment, T1 = after six months, T2 = after one year
of treatment. Symbols indicate statistical analysis between samples performed by Student’s t-test (GraphPad Prism 5.0 software) and values with
p < 0.05 were considered significantly
Table 1 Evaluation of frequency of infectious episodes at T0








Complete response 33 3 0
Partial response 15 2.2 1
Young subjects
Complete response 29 4 0
Partial response 19 4 1.6
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one year from the initial treatment. In this connection,
homeostasis of the immune response and recovery of im-
paired pro-inflammatory cytokine release, once initiated
by inhalation treatment, seems to persist with the time
and contributes to anti-microbial protection. By the way,
we are dealing with chronic patients also exposed to envir-
onmental antigens (pollutants, smoke, various allergens)
and, therefore, it is not surprising to uncover in this study
a condition of systemic involvement of the peripheral
blood immune response.
Actually, cURTI are sustained by a complex of microbes,
involving both respiratory viruses and co-infecting bac-
teria, thus leading to involvement of other organs, even
including gut (the so-called lung-gut axis) [54]. Chron-
icity of mucosal inflammation also leads to alteration of
gut microbiota with passage of bacterial products to
circulation, thus favoring a detectable systemic inflam-
mation [55].
In this direction, further studies should consider a longer
follow-up of patients in terms of immune system monitor-
ing and clinical evaluation, also including the assessment
of gut microbiota [56, 57].
Conclusion
The reduced frequency of infectious episodes in both
groups of cURTI patients following thermal water inha-
latory treatment may rely on the modulation of immune
responses in these patients. Our hypothesis is that in-
creased levels of IL-21 may trigger Th17 mediated release
of IL-17. Subsequent attraction of neutrophils may lead to
Fig. 9 Hypothetical model of immune modulation exerted by thermal water inhalation in elderly and young cURTI patients. The key result is represented
by the increased levels of IL-21 which may lead to an augmented secretion of IL-17. Subsequent recruitment of neutrophils may also restore reduced
serum levels of pro-inflammatory cytokines in patients. Consistent levels of IL-10, mainly produced by T regulatory cells, may restrain the
potential induction of an exaggerated inflammatory pathway
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an inflammatory wave of cytokines which restore the
otherwise impaired innate immunity in cURTI patients.
The consistent release of IL-10 may restrain the exagger-
ated inflammatory response at respiratory and systemic
levels (see Fig. 9).
Methods
Patient enrollment
In patients with cURTI, before inhalatory treatment, spe-
cifc diagnosis was made in public or private hospitals.
Major clinical manifestations of the upper respiratory
tract were represented by tonsillitis, pharyngitis, rhinitis,
sinusitis, otitis, common cold and, sometimes, bronchitis.
Patients with a diagnosis of cURTI (51 aged persons and
51 young individuals) were randomly assigned to undergo
inhalation treatment for 2 weeks in the thermal water
station “Margherita di Savoia” (Margherita di Savoia,
BAT, Italy). In both groups of patients, 3 dropouts were
recorded.
The main water solutes are the following: Br− (0.045 g/l);
Cl− (156 g/l) Na (85 g/l), SO4− (36 g/l); I−(0.0005 g/l); Ca
(0.38 g/l). Thermal water was free from bacterial contamin-
ation, and had a pH equal to 7.85.
Table 2 illustrates patient demographic information
and relevant clinical data. Patients with allergic disease
or dysmetabolic syndrome or had suffered a respiratory
infection or taken immunosuppressive drugs in the last
month were excluded. All participants gave an informed
consent and the study design was approved by the
Thermal Station ethical committee.
Inhalatory treatment
Nebulised thermal water under form of microparticles
(2–10 μm) prewarmed at 37 °C was administered through
the rhino-pharynx tubal unit once a day for 10 min for
2 weeks at 2–3° Baumè density.
Laboratory and clinical follow up
Peripheral blood from all patients was taken at enrollment
(T0), T1 (after 6 months) and T2 (after one year). Sera
were kept at −30 °C before use. As internal controls, 30
sera were obtained from young healthy donors (age range:
33–52) enrolled at the Blood Bank from Bari Polyclinic
Hospital (Bari, Italy). Other 20 sera were obtained from
healthy free-living elderly individuals (age range: 68–81)
following an informed consent.
Experimental design is depicted in Fig. 10.
Numbers of infectious episodes were recorded through
a specific questionnaire which each patient received at
the admission to the study.
Cytofluorimetric evaluation of serum cytokines
Serum cytokine determination was performed by a FAC-
SAria III cytofluorimetry (Becton & Dickinson, Milan,
Italy) utilizing the CBA Flexset kit (Becton & Dickinson).
The FCAP software was used and cytokines were expressed
in pg/ml.
Statistical analysis
Statistical analyses were performed by Student’s t-test
(GraphPad Prism 5.0 software) and values with p < 0.05
were considered significantly.
Fig. 10 Experimental design related to the inhalation therapy and serum cytokine assay in elderly and young cURTI patients. Inhalation therapy
with thermal water was based on a single cycle for two consecutive weeks. Serum cytokine evaluation was performed before treatment (T0) and
after six months (T1) and one year (T2) from inhalatory therapy
Table 2 Salient demographic and clinical features in elderly and
young patients with cURTI
Elderly Younger
Mean Age 68 48
Sex 27 F 24 M 28 F 23 M
Frequency of infectious episodes/year 3 (T0) 4(T0)
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